Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

LEXX
Lexaria Bioscience Corp. Common Stock
stock NASDAQ

At Close
Dec 24, 2025 12:26:14 PM EST
0.5600USD-9.710%(-0.0600)1,457,920
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Dec 26, 2025 8:41:30 AM EST
0.5474USD-2.250%(-0.0126)5,120
After-hours
Dec 24, 2025 4:54:30 PM EST
0.5600USD+0.036%(0.0000)19,891
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
08:00AM EST  IBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with   GlobeNewswire Inc
Dec 29, 2021
11:23AM EST  Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4; Dosing Expected To Begin By Apr. 2022   Benzinga
Dec 8, 2021
09:29AM EST  From Benzinga's Global Small Cap Conference: Lexaria Bioscience, Head Of IR, George Jurcic Says Co Has 99% Profit Margin On Its Royalties   Benzinga
09:29AM EST  From Benzinga's Global Small Cap Conference: Lexaria Bioscience, Head Of IR, George Jurcic Says Co Has 20 Patents And Has 50 Patents Pending Globally   Benzinga
09:27AM EST  From Benzinga's Global Small Cap Conference: Lexaria Bioscience, Head Of IR, George Jurcic Begins Presenting   Benzinga
07:33AM EST  Lexaria Issues Follow-U Results From Clinical Study Showing DehydraTECHTM-CBD Reduces Arterial Stiffness   Benzinga
Nov 10, 2021
09:10AM EST  Lexaria 2022 R&D Programs To Include Investigations Into Alzheimer's Disease And Diabetes   Benzinga
Nov 3, 2021
09:16AM EDT  Lexaria Shares Move Higher; Co Announces New Hypertension Study HYPER-H21-4   Benzinga
Nov 1, 2021
09:02AM EDT  Lexaria Bioscience Reports R&D Program To Compare Prescription Cannabidiol   Benzinga
Oct 13, 2021
01:38PM EDT  Lexaria Bioscience Reports Recent Oral THC Absorption Study Revealed Its DehydraTECH Required 15 Mins. To Deliver THC Levels In Blood Plasma   Benzinga
Oct 12, 2021
08:17AM EDT  via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofThe Stock2Me Podcastas part of its sustained effort to provide specialized content distribution via widespread syndication channels.   GlobeNewswire Inc
Oct 11, 2021
09:41AM EDT  LEXX: Lexaria's DehydraTECH Shows Fast Delivery   Benzinga
Oct 5, 2021
09:31AM EDT  Lexaria Announces Oral Nicotine Study NIC-A21-1 Results; Says 'DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls'   Benzinga
Sep 23, 2021
02:22PM EDT  LEXX: An Investment That's Easy to Swallow   Benzinga
Sep 8, 2021
07:19AM EDT  Lexaria Begins Investigational New Drug Enabling Program For DehydraTECH-CBD For Hypertension   Benzinga
07:19AM EDT  Lexaria Begins Investigational New Drug (IND) Enabling Program For DehydraTECH-CBD For Hypertension   Benzinga
Sep 7, 2021
06:54PM EDT  Lexaria Bioscience Corp. Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction With CBD   Benzinga
12:17PM EDT  CBDNewsBreaks Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction   Benzinga
11:09AM EDT  Shares of Lexaria Bioscience Corp. (LEXX) gained over 6% on Tuesday morning after the company reported positive initial data from human clinical study HYPER-H21-2 evaluating DehydraTECHTM-processed cannabidiol for potential application against hypertension.   RTTNews
09:33AM EDT  Why Lexaria Bioscience Shares Are Trading Higher Today   Benzinga
07:13AM EDT  Lexaria Bioscience Announces Initial Results From Human Clinical Study Of DehydraTECHTM; Study Evidences Up To 23% Decrease In Blood Pressure With DehydraTECH-CBD Relative to Placebo   Benzinga
Sep 2, 2021
11:24AM EDT  Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology   Benzinga
Aug 3, 2021
07:11AM EDT  Lexaria's DehydraTECH-CBD Lowers Blood Pressure   Benzinga
Aug 2, 2021
01:11AM EDT  DehydraTECH(TM) - Enabled Consumer Products Now Available in Over 7,000 Stores   Benzinga
Aug 1, 2021
08:01AM EDT  Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2   Benzinga
Jul 31, 2021
02:41PM EDT  Lexaria Receives US$3,817,643 From Warrant Exercises   Benzinga
Jul 29, 2021
08:00AM EDT  Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months   Benzinga
07:16AM EDT  Lexaria Highlights Results From Human Clinical Study Of HYPER-H21-1   Benzinga
Jul 28, 2021
07:10AM EDT  Lexaria Bioscience Earlier Announced Its DehydraTECH Technology Is Now Available For Sale In 7K+ Stores Across The US   Benzinga
Jul 27, 2021
11:13AM EDT  Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy   Benzinga
11:13AM EDT  Lexaria Completes Dosing In Human Clinical Study HYPER-H21-2   Benzinga
Jul 26, 2021
07:42AM EDT  Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3   Benzinga
Jul 21, 2021
07:24PM EDT  EXCLUSIVE: Lexaaria Biosciences CEO Chris Bunka Tells Benzinga that Use of DehydraTECH-enabled Colchcine Results in Increased Drug Delivery and Concentration Into the Bloodstream by 167% and 91% Respectively in Mitigating the Cytokine Storm Associated with SARS-CoV-2/COVID-19   Benzinga
12:15PM EDT  Mid-Day Market Update: Crude Oil Up 4%; Chembio Diagnostics Shares Spike Higher   Benzinga
10:47AM EDT  Mid-Morning Market Update: Markets Open Higher; Coca-Cola Tops Q2 Views   Benzinga
10:05AM EDT  Shares of Lexaria Bioscience Corp. (LEXX, LEXXW) are gaining over 45% on Wednesday morning after the company announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.   RTTNews
07:06AM EDT  Lexaria Highlights VIRAL-A20-3 STudy Results Showing 'Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects'   Benzinga
Jul 20, 2021
08:21AM EDT  Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council   Benzinga
Jul 18, 2021
07:21AM EDT  Lexaria Receives Patent Protection in Japan   Benzinga
Jul 15, 2021
08:50AM EDT  Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study   Benzinga
Jul 13, 2021
07:15AM EDT  Lexaria Granted Patent In Japan Titled 'Stable ready-to-drink beverage compositions comprising lipophilic active agents'   Benzinga
Jul 10, 2021
08:21AM EDT  Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets   Benzinga
Jul 7, 2021
11:27AM EDT  Lexaria Announces 2021 Annual Meeting Results   Benzinga
Jun 28, 2021
08:35AM EDT  Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com.   GlobeNewswire Inc
Jun 21, 2021
08:35AM EDT  Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.   GlobeNewswire Inc
Jun 20, 2021
07:11AM EDT  Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs   Benzinga
Jun 17, 2021
08:33AM EDT  Lexaria Says An IC50 In Vitro Study Was Completed With Remdesivir And Ebastine And Concluded 'their formulation and processing methodology "did not negate the known efficacy of those compounds."'   Benzinga
Jun 14, 2021
07:01AM EDT  Lexaria Provides Progress Report on Six R&D Programs   Benzinga
Jun 13, 2021
11:01AM EDT  Lexaria Announces Issuance of Options   Benzinga
Jun 12, 2021
07:11AM EDT  Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1   Benzinga
Jun 8, 2021
08:22AM EDT  Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus   Benzinga
Jun 7, 2021
07:11AM EDT  Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1   Benzinga
Jun 3, 2021
08:14AM EDT  Lexaria Bioscience on Drug Delivery Technology and its Patented DehydraTECH   Benzinga
07:06AM EDT  Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus   Benzinga
Jun 2, 2021
12:10PM EDT  Lexaria's DehydraTECHTM Drug Delivery Technology Is Investigating Applications in Multiple Markets Valued Over USD $100 Billion   Benzinga
May 28, 2021
11:18AM EDT  Video: Benzinga Cannabis Hour, Nasdaq Edition Ft. The Alkaline Water Company, Lexaria Bioscience   Benzinga
May 27, 2021
05:20PM EDT  VIDEO: Benzinga Cannabis Hour | Nasdaq Edition Ft. The Alkaline Water Company And Lexaria Bioscience   Benzinga
May 25, 2021
07:11AM EDT  Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever   Benzinga
May 20, 2021
07:11AM EDT  Lexaria Bioscience Announces Its DehydraTECH 2.0 Formulation Delivered Up To 2,708% More CBD Into Bloodstream Than Standard MCT Control Formulation   Benzinga
May 17, 2021
07:41AM EDT  Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted   Benzinga
May 12, 2021
10:11AM EDT  Lexaria Announces Cancellation of Options   Benzinga
09:31AM EDT  Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET   Benzinga
May 11, 2021
08:11AM EDT  Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1   Benzinga
May 6, 2021
10:19AM EDT  Mid-Morning Market Update: Markets Mostly Lower; Kellogg Earnings Beat Views   Benzinga
May 1, 2021
11:01AM EDT  Lexaria Awards Stock Options   Benzinga
Apr 27, 2021
08:00AM EDT  Lexaria Commences Human Clinical Hypertension Study   Benzinga
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 20, 2021
04:32PM EDT  Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants   Benzinga
Apr 19, 2021
01:31AM EDT  Lexaria's DehydraTECH(TM) Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 12, 2021
07:24PM EDT  Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets   Benzinga
Apr 9, 2021
03:36PM EDT  Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021   Benzinga
03:36PM EDT  Rapid Progress in Hypertension Studies by Lexaria   Benzinga
03:36PM EDT  Lexaria's Antiviral Drug Evaluation Program Progressing   Benzinga
03:36PM EDT  Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET   Benzinga
03:36PM EDT  Lexaria Technology Generates Positive Stability Testing for World-Class Ready to Drink CBD Beverages   Benzinga
Apr 6, 2021
07:10AM EDT  Lexaria Bioscience To Begin Applied Research And Development Programs Planned In 2021   Benzinga
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 24, 2021
07:08AM EDT  Lexaria Bioscience Announces Results From Stability Testing; Says DehydraTECH CBD-Beverage Demonstrates 93.4% Potency One Year After Production   Benzinga
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
Mar 15, 2021
07:09AM EDT  Lexaria Bioscience Highlights Progress In Hypertension Studies, Says All Five Studies Examining DehydraTECHTM CBD For Hypertension Are Underway   Benzinga
Mar 2, 2021
09:57AM EST  Lexaria Bioscience Corp. is Changing the Future of Drug Delivery   Benzinga
Feb 17, 2021
09:06AM EST  Enhancing Drug Delivery Systems With Lexaria's Technology   Benzinga
Feb 16, 2021
06:08AM EST  Lexaria Bioscience $11 Mln Financing Supports R&D Program Targeting High Blood Pressure And SARS-CoV-2 Infection   RTTNews
06:01AM EST  Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D   PR Newswire
Jan 12, 2021
02:31PM EST  Mid-Afternoon Market Update: Dow Rises 50 Points; Qilian International Shares Spike Higher   Benzinga
12:27PM EST  Mid-Day Market Update: VOXX International Jumps Following Q3 Earnings; RedHill Biopharma Shares Slide   Benzinga
10:22AM EST  Mid-Morning Market Update: Markets Edge Higher; Albertsons Earnings Beat Expectations   Benzinga
07:13AM EST  Lexaria Bioscience Announces Public Offering of ~1.83M Units At $5.25/Unit; Gross Proceeds Expected To Be $9.6M   Benzinga
07:01AM EST  Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC